Adequately powered, randomized phase III trials are necessary to define the clinical role of
targeted therapies in advanced gastric cancer. Biomarker studies to correlate with treatment …

Simple Summary Outcomes for patients with advanced gastric cancer continue to be
unsatisfactory despite the inclusion of new targeted therapies in the treatment options. The …

Introduction: Despite significant improvements in systemic chemotherapy over the last two
decades, the prognosis of patients with advanced disease remains dismal. Collaborative …

No standard adjuvant or palliative chemotherapy regimen has been internationally
approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is …

The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in
recent years. We have reviewed the recent data of clinical trial incorporating targeted …

In the West in particular, the vast majority of gastric cancer (GC) patients present with
advanced-stage disease. Although combination chemotherapy is still the most important …

In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still
remains one of the leading causes of cancer mortality. Great efforts have been made to …

Gastric cancer currently ranks fourth in cancer-related mortality worldwide. In the western
world, it is most often diagnosed at an advanced stage, after becoming metastatic at distant …

Despite the great progress in the treatment of gastric cancer, it is still the third leading cause
of cancer death worldwide. Patients often miss the opportunity for a surgical cure, because …

Gastric cancer is responsible for a high burden of disease globally. Although more extensive
use of chemotherapy together with the recent introduction of the two targeted agents …